Dafinchi AI

Stryker Corporation

SYK

Healthcare

2w

Financial Performance Summary

Adjusted EPS was $3.13, up 11.4% year-over-year, partially offset by higher interest expense.
Adjusted gross margin improved by 120 basis points to 65.4%, driven by cost improvements and business mix.
Adjusted operating margin was 25.7%, up 110 basis points from Q2 2024.
Foreign currency had a favorable impact on sales (0.8%) and EPS ($0.04).
International organic sales growth was 6.5%, with notable contributions from South Korea and emerging markets despite supply chain challenges.
MedSurg and Neurotechnology segment grew organically by 11%, with 12.5% U.S. growth and 5.7% international growth.
Orthopedics segment had 9% organic growth, including 9.7% U.S. and 7.5% international growth.
Stryker delivered double-digit organic sales growth of 10.2% and adjusted EPS growth of 11.4% in Q2 2025.
U.S. organic sales growth was 11.5%, driven by double-digit growth in Endoscopy, neurocranial, Trauma and extremities, and instruments businesses.
Year-to-date cash from operations was $1.4 billion, driven by higher net earnings and working capital improvements.

Halozyme Therapeutics, Inc.

HALO

Healthcare

1w

Record Revenue Growth Driven by Key Blockbusters and New Catalysts

Total revenue of $326 million, up 41% year-over-year, driven by strong royalty performance.
Royalty revenue increased 65% to $206 million, fueled by DARZALEX, Phesgo, and VYVGART Hytrulo.
Multiple new product approvals and reimbursement milestones in Europe and China created revenue inflections.
DARZALEX subcutaneous reached 96% conversion in the US, with ongoing growth in frontline and early-stage indications.
Phesgo revenue grew 55% to CHF 1.2 billion, with increased global adoption and label expansion in Europe.
VYVGART Hytrulo sales surged 97% to $949 million, with expansion into new indications and markets.
Johnson & Johnson's RYBREVANT subcutaneous revenue doubled YoY to $179 million, with strong launch uptake.
Multiple other ENHANZE-enabled products, including OCREVUS ZUNOVO, Tecentriq Hybreza, and OPDIVO Qvantig, are early in their growth phases.
Guidance raised twice in 2025, now projecting total revenue of $1.275-$1.355 billion, with royalty revenue leading growth.
Share repurchases of over $303 million in Q2, totaling more than $1.85 billion since 2019, supporting capital return strategy.

Kiniksa Pharmaceuticals, Ltd.

KNSA

Healthcare

2w

Financial Performance Summary

ARCALYST collaboration profit grew 75% year-over-year to $104.8 million in Q2 2025, driven by sales volume and disciplined commercial investments.
ARCALYST net revenue was $156.8 million in Q2 2025, a 52% year-over-year increase driven by new patient enrollments, prescribers, and active commercial patients.
Cash balance increased by approximately $40 million to $307.8 million in Q2 2025, with expectations to remain cash flow positive on an annual basis.
Net income was $17.8 million in Q2 2025 compared to a net loss of $3.9 million a year ago, reflecting strong revenue growth and moderate expense growth.
Operating expenses grew 26% year-over-year due to cost of goods sold, collaboration expenses, and SG&A supporting ARCALYST commercialization.

DCGO

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA was a loss of $6.1 million compared to a positive $17.2 million in Q2 2024.
Adjusted gross margin was 31.6% in Q2 2025 versus 33.9% in Q2 2024, with Mobile Health margins improving sequentially but down year-over-year.
Medical Transportation Services revenue increased to $49.6 million from $48.2 million year-over-year, with a 7% underlying growth excluding Colorado exit.
Mobile Health revenue declined to $30.8 million from $116.7 million year-over-year, driven by reduced migrant-related revenues.
SG&A expenses decreased 7% year-over-year and 5% sequentially on an absolute basis, with recurring SG&A down 9% sequentially and 18% year-over-year.
Strong cash flow from operations of $33.6 million in Q2 2025, with total cash and equivalents rising to $128.7 million.
Total revenue for Q2 2025 was $80.4 million, down from $164.9 million in Q2 2024, primarily due to the wind down of migrant-related government programs.